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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the safety of antidepressant use, compared with placebo or psychological therapy, for the treatment of pre-existing and ante-
natal depression during pregnancy.
To assess the effectiveness of antidepressant use, compared with placebo or psychological therapy, for the treatment of pre-existing and
ante-natal depression during pregnancy.
B A C K G R O U N D
Description of the condition
Depression is a highly prevalent mood disorder associated with so-
cial, human and economic costs, and public health impact world-
wide. According to the World Health Organization (WHO), de-
pression is estimated to affect more than 350 million people glob-
ally (WHO 2010a). The life-time risk of developing depression is
10% to 20% in females and slightly less in males (WHO 2010a).
Despite the seriousness of depression as a disease and the availabil-
ity of effective treatments, less than half of cases worldwide receive
appropriate care (WHO 2010a).
Current theories on the causes of depression remain controversial,
however, genetic predisposition, chronic disease and disability, en-
vironmental factors, an individual’s ability to cope with difficult
situations, direct biochemical changes in the brain and early child-
hood experiences have all been shown to potentially contribute
to the onset of depression (beyondblue 2013; Black Dog Institute
2013; Passer 2008).
Depression can be diagnosed by a psychologist, psychiatrist or pri-
mary health care provider, usually in conjunction with symptom
related scales such as the Beck Depression Inventory (BDI) (Beck
1961), or the Edinburgh Postnatal Depression Scale (EPDS) (also
used to assess antenatal depression) (Cox 1994). However, symp-
tom scales alone cannot be used as a direct diagnostic tool although
for research purposes these tools are often used to assess improve-
ments or decline in depressive symptoms.
Depression is one of the most common complications of the pre-
natal period (Gaynes 2005). Rates of depression during preg-
nancy range from between 7.4% and 12% and rise from the first
trimester, to the second and third trimester (Bennett 2004;Gaynes
2005).
The morbidity of depression during pregnancy, as well as the neg-
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ative effects of depression on subsequent fetal, infant and child
development and on the family and community as a whole, have
been extensively recognised (Cooper 1998;Cox1982;Grote 2010;
O’Connor 2007; O’Hara 1990; Marcus 2009a; Marcus 2009b).
Antenatal depression has been associated with maternal substance
use and increased risk of preterm birth and low birthweight (Grote
2010; Marcus 2009a; Marcus 2009b; Woods 2010). Prenatal de-
pression also results in reduced total sleep time, night time awak-
enings, and sleep problems being identified at 6, 18, and 30
months of age in subsequent infants and is related to severity,
with higher levels of prenatal maternal depression predictive of
more sleep problems at 18 and 30 months (O’Connor 2007),
possibly as a result of modifications to neurodevelopmental pro-
gramming (Ponder 2011). In addition, disturbed infant sleep has
been shown to further contribute to postnatal depression (PND)
(Dennis 2005).
There is a well-established relationship between antenatal depres-
sion and the development of PND, with antenatal depression
being the strongest predictor of PND (Beck 1996; Beck 2001;
O’Hara 1996). PND is a debilitating and costly condition, has
an immediate primary effect on child well-being, parenting effi-
cacy, use of safe parenting practices andmarital conflict. Secondary
effects of increased problematic behaviours and poorer cognitive
development in childhood may occur due to poorer attachment
and reduced maternal engagement (Murray 1996). Moreover, it is
increasingly recognised that some women who become depressed
postnatally have, in retrospect, been depressed during the antena-
tal period (Evans 2001; Kumar 1984). Large studies have shown
that rates of depression in late pregnancy in particular, are as high,
or higher, than rates of postpartum depression (DaCosta 2000;
Evans 2001; Josefsson 2001; Zuckerman 1989). It is therefore im-
portant to detect and treat symptoms of antenatal depression to
reduce the incidence of PND.
Depressed mood during pregnancy has also been associated with
poor attendance at antenatal clinics (Phillippi 2009). Despite this
potential for poor antenatal attendance, the antenatal period pro-
vides an opportunity for prevention and management of depres-
sion as a result of frequent contact with health professionals. Ade-
quate management of antenatal depression has the potential to re-
duce maternal substance use, prevent preterm birth and low birth
weight as well as PND and its associated consequences. This in-
formation in combination with the ineffective treatment of de-
pression, highlights a need to focus recommendations for clinical
practice to treat depression in this vulnerable population of preg-
nant women (Muzik 2009a; Muzik 2009b).
Description of the intervention
Antidepressants are commonly prescribed to treat depression
(Centre for Disease Control 2011). They include monoamine
oxidase inhibitors, tricyclic antidepressants, tetracyclic antide-
pressants, selective serotonin reuptake inhibitors, serotonin-nore-
pinephrine reuptake inhibitors and others (e.g. bupropion). Based
on data from the United States, antidepressant use during preg-
nancy has increased from 2% of pregnancies in 1996 to 7.6% of
pregnancies in 2005 (Andrade 2008).
Antidepressants can be used alone or more commonly in con-
junction with psychosocial and psychological therapies such as be-
havioural therapy (includes behavioural activation), cognitive be-
havioural therapy, mindfulness-based cognitive behavioural ther-
apy (including acceptance commitment therapy), and psychody-
namic, humanistic (including motivational interviewing) and in-
tegrative therapies (includes interpersonal therapy) (Arroll 2009;
Cipriani 2009; Cipriani 2010; Guaiana 2007;Magni 2013; NICE
2007). Patient responses vary markedly to different classes of an-
tidepressants and therefore this will influence the type of antide-
pressant drug that is prescribed for an individual. Dosage regimes
differ between the different classes of antidepressants, and alsowith
the severity of depression. Antidepressants are typically taken daily,
with the type of antidepressant determining whether or not night
time or morning dosing is appropriate. The length of time antide-
pressants are taken for may vary, ranging from several months to
several years, or lifetime use (FDA 2010; Elsevier 2013).
As with the general population, antidepressants during pregnancy
can be used alone or in combination with psychological thera-
pies (NICE 2007). Psychological therapy alone can in some cases
be appropriate for some women, but others may need pharma-
cological treatment (NICE 2007; Yonkers 2009). Decisions sur-
rounding the use of antidepressants during pregnancy are incred-
ibly complex, requiring a careful balance of optimising maternal
health while minimising potential risks to the developing fetus.
However, data concerning the immediate risks of antidepressants
to the fetus are limited, and little is known about the potential
long-term risks.
There is much debate concerning the potential increased risk of
congenital malformations following the use of paroxetine during
pregnancy (Berard 2010; Scialli 2010; Wurst 2010), as well as for
the remainder of antidepressants (despite a lack of clear evidence
that they are teratogenic); due to study designs used there can be no
determination of causality (Ellfolk 2010; Nguyen 2010; Pedersen
2009; Udechuku 2010). However, there is evidence that antide-
pressant use during pregnancy may be associated with an increased
risk of a range of adverse pregnancy outcomes including sponta-
neous abortion (Berard 2010a; Nakhai-Pour 2010), preterm birth
(Lund 2009), and low birth weight (Lattimore 2005), but sep-
arating these outcomes from the effects of depression itself dur-
ing pregnancy has been challenging (Ellfolk 2010; Nguyen 2010;
Udechuku 2010). Furthermore, exposure to antidepressants dur-
ing late gestation is associated with an increased risk of admission
to special care nurseries and neonatal intensive care units as a result
of neonatal abstinence syndrome and/or poor neonatal adaptation,
which are usually mild and self-limiting (Costei 2002; Heikkinen
2003; Kallen 2004; Laine 2003; Lattimore 2005; Nguyen 2010;
Udechuku 2010; Zeskind 2004). Other perinatal complications
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include the reported increased risk of persistent pulmonary hy-
pertension of the newborn following prenatal exposure to selec-
tive serotonin reuptake inhibitors in particular, with the great-
est risk attributed to those exposed later in pregnancy (Chambers
2006; Nguyen 2010; Udechuku 2010). Finally, based on the small
number of studies available, antidepressant use during pregnancy
does not appear to adversely influence developmental outcomes in
the offspring; however, major differences in study design, patterns
of antidepressant use, age at follow-up, outcome measures used
and adjustment for confounding make it difficult to reach any
strong conclusions (Ellfolk 2010; Gentile 2011; Nguyen 2010;
Udechuku 2010).
How the intervention might work
Antidepressants exert their action in a number of different ways
depending on the specific type of antidepressant. However, all
have an underlying mechanism whereby they effect monoamine
transmitter deficits within the brain (Rang 2007).
Antidepressants are organised into classes for the purposes of
this review as follows. Tricyclic antidepressants exert their actions
through inhibiting uptake of noradrenaline, and or serotonin. Se-
lective serotonin reuptake inhibitors exert their actions through in-
hibiting uptake of serotonin. Serotonin norepinephrine reuptake
inhibitors exert their actions through inhibiting uptake of nora-
drenaline and serotonin. Noradrenergic and specific serotonergic
antidepressants exert their actions through blocking the action of
noradrenaline and serotonin at their receptors. Monoamine oxi-
dase inhibitors and reversible inhibitors of monoamine oxidase A
exert their actions through inhibition of one or both forms of the
enzyme monoamine oxidase.
It may also be speculated that antidepressants exert some of their
antidepressant effects through their negative immunoregulatory
capacities (Maes 2001). Much of the research investigating the
effects of antidepressants on inflammation has focused on the se-
lective serotonin reuptake inhibitors, in particular fluoxetine. Ani-
mal studies have shown that fluoxetine may be a therapeutic agent
to manage inflammatory bowel disease by significantly inhibiting
activated nuclear factor kappa B signals and the up-regulated ex-
pression of interleukin-8 in intestinal epithelial cells (Koh 2011).
Sluzewska 1995 reported changes in serum levels of interleukin-
6 as well as levels of C-reactive protein, alpha1-acid glycoprotein
and its degree of microheterogeneity before and after treatment
with fluoxetine 20 mg daily over an eight-week period. Following
treatment of selective serotonin reuptake inhibitors for major de-
pression over a four-week period, O’Brien 2006 also observed a
significant drop in C-reactive protein concentrations whether or
not the depression resolves. These findings indicate that antide-
pressants can induce an anti-inflammatory response independent
of antidepressant action.
Why it is important to do this review
The decision to begin, maintain or discontinue antidepressant
treatment after a pregnancy is confirmed should take into account
the severity of depression, the risk of relapse, and the specific drug
safety data available.However, it has been shown that two-thirds of
women whose depression was well stabilised and who interrupted,
or discontinued their antidepressant treatment before conception,
relapsed during pregnancy, compared to one quarter of women
who maintained their treatment (Cohen 2006). This highlights
the need to undertake, and or, continue antidepressant treatment
for those women who develop depression in the antenatal period,
and those women who already have a pre-existing depressive dis-
order prior to conception, respectively. However, with a lack of
certainty in this area, a systematic review needs to be undertaken
to assess the safety and efficacy of antidepressant use during preg-
nancy to determine potential side effects and the most effective
pharmacological intervention to manage depressive symptoms in
this population.
While Cochrane systematic reviews have been undertaken in the
area of treatment strategies for mental health problems during
pregnancy (Dennis 2007), there are currently no systematic re-
views listed that address the use of pharmacological interventions
to treat depression during pregnancy. This includes pre-existing
depression (i.e. themother was depressed prior to conception) and
antenatal depression (i.e. the mother became depressed follow-
ing conception). Cochrane systematic reviews have been presented
that focus on and discuss antidepressant use for the prevention
and treatment of postnatal depression (Hoffbrand 2001; Howard
2005); however, there are no reviews that target depression in the
antenatal period. The proposed systematic review aims to focus
on this area in particular.
Other non-Cochrane reviews that assess the use of antidepressants
during pregnancy have been published. However, these tend to
focus on one type of antidepressant alone. While, those that have
been performed assessing all types of antidepressants appear to
be lacking in their approach and are of poor quality (Simoncelli
2010).
Lack of high quality evidence surrounding the safety (as defined in
this instance as a lack of adverse events) and efficacy of antidepres-
sants during pregnancy increases therapeutic uncertainty, making
it difficult to accurately balance the risks and benefits associated
with treatment. This may result in decisions to cease antidepres-
sant use during pregnancy, even in situations where treatment is
considered necessary. We are however aware of the potential eth-
ical implications of conducting randomised controlled trials dur-
ing pregnancy which may impact on the ability to identify these
types of studies during pregnancy. As such we have acknowledged
this by expanding inclusion of studies to be assessed in this review
to include non-randomised studies.
Therefore, a systematic review of the safety and efficacy of antide-
pressants during pregnancy is required to bring together the rel-
evant evidence for people wishing to make a well-informed deci-
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sion. This would enable strengthened safety data, support medi-
cation use during pregnancy when necessary and allow healthcare
professionals and women to be adequately informed of the true
risks and benefits associated with treatment.
O B J E C T I V E S
To assess the safety of antidepressant use, compared with placebo
or psychological therapy, for the treatment of pre-existing and
ante-natal depression during pregnancy.
To assess the effectiveness of antidepressant use, compared with
placebo or psychological therapy, for the treatment of pre-existing
and ante-natal depression during pregnancy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised controlled trials, and
non-randomised controlled prospective and retrospective studies
including cohort and case control studies.
Types of participants
Women of all ages who are pregnant and:
• who have a diagnosis of depression based on established
diagnostic criteria (Diagnostic and Statistical Manual of Mental
Disorders-Text Revision (DSM-IV-TR) or the International
Classification of Disease (ICD10) (APA 2000; WHO 2010b);
• who had pre-existing depressive symptoms prior to
pregnancy conception;
• who have developed depressive symptoms in the antenatal
period.
We will use depression screening tools and scales e.g. EPDS (Cox
1994), estimates of depression by recognised diagnostic schemes,
or by other standardised criteria, including the Research Diag-
nostic Criteria (RDC), as an indicator of depression severity. The
threshold scores used for the respective scales will be those used
by the investigators in the trials as discussed in previous Cochrane
Reviews in relation to assessment of antidepressants (Hoffbrand
2001). We will include all women that had been taking antide-
pressants of any kind during their pregnancy.Women taking other
psychoactive substances, and/or with co-morbidities (for example
diabetes, asthma), and/or taking medication for these respective
conditions will not be excluded, however, these will be analysed
and discussed separately at the time of analysis.
We will exclude women prescribed antidepressants as a preventa-
tive intervention.
Types of interventions
Experimental interventions (used alone or in combination)
We will include the following types of antidepressants (all dose
ranges and preparations).
• Tricyclic antidepressants: amitriptyline, imipramine,
trimipramine, doxepin, desipramine, protriptyline, nortriptyline,
clomipramine, dothiepin, iofepramine.
• Selective serotonin re-uptake inhibitors: zimelidine
(worldwide ban), fluvoxamine, fluoxetine, paroxetine, sertraline ,
citalopram, escitalopram.
• Serotonin-norepinephrine reuptake inhibitors: venlafaxine,
milnacipram, duloxetine.
• Noradrenergic and specific serotonergic antidepressants:
mirtazapine.
• Monoamine oxidase inhibitors: (a) irreversible: phenelzine,
tranylcipromine, izocarboxazid; (b) reversible: brofaramine,
moclobemide, tyrima.
• Other antidepressants:
◦ noradrenaline reuptake inhibitors: reboxetine,
atomoxetine;
◦ norepinephrine-dopamine reuptake inhibitors:
amineptine, bupropion;
◦ serotonin antagonist and reuptake inhibitors:
trazodone;
◦ unclassified: agomelatine, vilazodone;
◦ other heterocyclic antidepressants: mianserin,
amoxapine, maprotiline.
Comparator interventions
• Placebo.
• Psychological therapies (e.g. behavioural therapy (including
behavioural activation)), cognitive behavioural therapy,
mindfulness-based cognitive behavioural therapy (including
acceptance commitment therapy), and psychodynamic,
humanistic (includes motivational interviewing) and integrative
therapies (including interpersonal therapy).
Types of outcome measures
Primary outcomes
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Maternal outcomes
1. Safety
• Maternal mortality and serious morbidity including self-
harm and suicide attempts.
• Maternal complications of pregnancy (i.e. pre-eclampsia).
• Spontaneous abortion / miscarriage.
2. Effectiveness
Clinical response to antidepressant as observed by a reduction and
or improvement in depression (as defined in individual studies
according to validated scales used to assess depression (e.g. the
Beck Depression Inventory (Beck 1961), the Edinburgh Postnatal
Depression Scale (Cox 1994), and their subsequent scoring and
cut off protocols). Effectiveness can be measured as “responded”
versus “not responded”.
Neonatal outcome
3. Safety
• Neonatal mortality (death of neonate).
• Neonatal morbidity (adverse events not including mortality
e.g. congenital malformations (as defined by individual studies)).
Neonates are defined as infants of four weeks of age or less.
Secondary outcomes
Maternal outcome
4. Effectiveness
• Clinical response to antidepressant as observed by a
reduction and or improvement in depression (as defined in
individual studies according to validated scales used to assess
depression (e.g. BDI (Beck 1961), EPDS (Cox 1994), and their
subsequent scoring).
• Effectiveness will be assessed in this instance on a
continuous scale of increasing or decreasing score.
• Improvement in the ability of the mother to carry out daily
activities and social functioning e.g. Global Assessment of
Functioning (GAF) (APA 2000).
• Acceptability and maternal satisfaction of treatment both as
assessed directly by questioning trial participants and indirectly
by the drop-out rates.
• Maternal/neonate attachment.
Neonatal outcome
5. Safety
• Neonatal abstinence syndrome.
• Gestational age at birth (preterm delivery).
• Birth weight (small-for-gestational age).
• Neonatal development both physical and cognitive (as
variously defined and measured).
• Mother/neonate attachment.
Search methods for identification of studies
The Cochrane Depression, Anxiety and Neurosis
Review Group’s Specialised Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CC-
DAN)maintain two clinical trials registers at their editorial base in
Bristol, UK: a references register and a studies based register. The
CCDANCTR-References Register contains over 31,500 reports
of RCTs in depression, anxiety and neurosis. Approximately 65%
of these references have been tagged to individual, coded trials.
The coded trials are held in the CCDANCTR-Studies Register
and records are linked between the two registers through the use
of unique Study ID tags. Coding of trials is based on the EU-Psi
coding manual, using a controlled vocabulary, please contact the
CCDAN Trials Search Coordinator for further details. Reports
of trials for inclusion in the Group’s registers are collated from
routine (weekly), generic searches of MEDLINE (1950-), EM-
BASE (1974-) and PsycINFO (1967-); quarterly searches of the
Cochrane Central Register of Controlled Trials (CENTRAL) and
review specific searches of additional databases. Reports of trials
are also sourced from international trials registers c/o the World
Health Organization’s trials portal (the International Clinical Tri-
als Registry Platform (ICTRP)), pharmaceutical companies, the
handsearching of key journals, conference proceedings and other
(non-Cochrane) systematic reviews and meta-analyses.
Details of CCDAN’s generic search strategies (used to identify
RCTs) can be found on the Group’s website.
Electronic searches
The CCDANCTR-Studies Register will be searched using the
following terms:
Diagnosis = (depress* or dysthymi*) and Concomitant Condition
= pregnancy
OR
Diagnosis = “Depression, Antenatal” or “Depression, Perinatal”
AND
Intervention = antidepress* or anti-depress* or “anti depress*” or
MAO* or RIMA* or “monoamine oxidase inhibit*” or ((sero-
tonin or norepinephrine or noradrenaline or neurotransmitt* or
dopamin*) and (uptake or reuptake or re-uptake or “re uptake”))
or SSRI* or SNRI* or NARI* or SARI* or NDRI* or TCA* or
tricyclic* or tetracyclic* or pharmacotherap* or psychotropic* or
“drug therapy”) or (Agomelatine or Alaproclate or Amoxapine or
Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxe-
tine or Befloxatone or Benactyzine or Binospirone or Brofaromine
or (Bupropion or Amfebutamone) or Butriptyline or Caroxa-
zone or Cianopramine or Cilobamine or Cimoxatone or Citalo-
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pram or (Chlorimipramin* or Clomipramin* or Chlomipramin*
or Clomipramine) or Clorgyline or Clovoxamine or (CX157
or Tyrima) or Demexiptiline or Deprenyl or (Desipramin* or
Pertofrane) or Desvenlafaxine or Dibenzepin or Diclofensine or
Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxe-
tine or Desvenlafaxine or DVS-233 or Escitalopram or Etoperi-
done or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine
or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocar-
boxazid* or Levomilnacipran or Lofepramin* or (“Lu AA21004”
orVortioxetine) or “LuAA24530” or (LY2216684 or Edivoxetine)
or Maprotiline or Melitracen or Metapramine or Mianserin or
Milnacipran orMinaprine orMirtazapine orMoclobemide orNe-
fazodone or Nialamide or Nitroxazepine or Nomifensine or Nor-
fenfluramine orNortriptylin* orNoxiptilin* orOpipramol orOx-
aflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezine
or Pirlindole or Pivagabine or Pizotyline or Propizepine or Pro-
triptylin* or Quinupramine or Reboxetine or Rolipram or Scopo-
lamine or Selegiline or Sertraline or Setiptiline or Teciptiline or
Thozalinone or Tianeptin*or Toloxatone or Tranylcypromin* or
Trazodone or Trimipramine or Venlafaxine or Viloxazine or Vila-
zodone or Viqualine or Zalospirone))
TheCCDANCTR-ReferencesRegisterwill be searchedusing sim-
ilar terms in the title, abstract and keywords fields.
Additional searches will be conducted on the ’Specialized regis-
ter’ of the Cochrane Pregnancy and Childbirth Review Group,
MIDIRS Midwifery Database, CINAHL, LILACS, PSYNDEX
and Open SIGLE.
TheWHOTrials portal (ICTRP) together with ClinicalTrials.gov
will also be searched to identify any unpublished or ongoing stud-
ies.
A cited reference search, of reports of all included studies, will
be conducted on the Web of Science to identify any outstanding
reports of trials.
Searching other resources
Handsearches
1. Reference lists of identified studies
2. Relevant book chapters and their bibliographies
3. Conference proceedings
List of book titles:
• Pregnant on Prozac: The Essential Guide to Making the
Best Decision for You and Your Baby (Bennett 2009);
• Pregnancy Blues: What Every Woman Needs to Know
about Depression During Pregnancy (Misri 2006);
• The New Antidepressants and Antianxieties (Appleton
2004);
• Medication Safety in Pregnancy and Breastfeeding (Koren,
Medication Safety in Pregnancy and Breastfeeding) (Koren
2006);
• A Deeper Shade of Blue: A Woman’s Guide to Recognizing
and Treating Depression in Her Childbearing Years (Nonacs
2006);
• What Am I Thinking? Having a Baby After Postpartum
Depression (Kleiman 2005);
• Psychiatric Disorders in Pregnancy and the Postpartum:
Principles and Treatment (Current Clinical Practice) (Hendrick
2010);
• When Baby Brings the Blues: Solutions for Postpartum
Depression (Dalfen 2008);
• Depression in New Mothers: Causes, Consequences, and
Treatment Alternatives (Kendall-Tackett 2010).
List of conference proceedings:
• Perinatal Society of Australia and New Zealand;
• Australian College of Midwives;
• International Confederation of Midwives.
Personal communication
• We will contact pharmaceutical companies directly for any
relevant unpublished data. Companies include:
◦ Approved Prescription Services Ltd, Ashbourne
Pharmaceuticals Ltd, Cambridge Laboratories, Cox
Pharmaceuticals, Generics (UK) Ltd, Goldshield
Pharmaceuticals Ltd, Hansam Healthcare Ltd, Hoechst Marion
Roussel Ltd, Knoll Pharmaceutical Ltd, Eli Lilly & Co Ltd,
Lundbeck Ltd, E.Merck Pharmaceuticals, Merck Sharp &
Dohme Ltd, H N Norton & Co Ltd, Novartis Pharmaceuticals
UK Ltd, Organon Laboratories Ltd, Parke-Davis Medical, Pfizer
Ltd, Pharmacia & Upjohn Ltd, Roche Products Ltd, Rosemont
Pharmaceuticals Ltd, Sanofi Winthrop Ltd, Smithkline Beecham
Pharmaceuticals, SolvayHealthcare Ltd, UCBPharma Ltd,
Wyeth Laboratories, AstraZeneca.
• We will also contact authors of identified trials and with
experts in the field including a search for non-English material.
Data collection and analysis
Selection of studies
Abstracts of studies identified in the above search will be examined
by all four authors. We will obtain the full-text reports of studies
that are potentially relevant; trials under consideration will be as-
sessed for whether they fulfil the inclusion criteria and method-
ological quality without regard to their results. Where the authors
disagree, the matter will be discussed until agreement is reached.
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Where two authors disagree on the inclusion of a study, a third au-
thor will be invited to determine the inclusion of the study.Where
necessary the matter will be discussed with all authors until agree-
ment is reached. As four authors are to be included on this review,
where a situation occurs where there is no majority decision or a
split in the decision to include a study, the Cochrane Depression,
Anxiety and Neurosis Group will be contacted for further consul-
tation.
The process of study selection will be documented and reported
using a PRISMA flow diagram.
Data extraction and management
We will design data extraction forms for the purpose of recording
descriptive information, summary statistics of the outcome mea-
sures, the quality scale ratings, and associated commentary. Once
extracted, we will enter the data into the Cochrane Collaboration’s
statistical software, Review Manager 2013, to conduct any meta-
analysis. Where information is missing, we will contact investiga-
tors by email in an attempt to obtain this information.
We will present and compare studies under two separate headings:
(1) randomised trials; and (2) non-randomised trials (e.g. cohort
and case control trials), with the analyses presented separately for
each subgroup.
We will collate the following information from randomised trials.
1. Description of the trials, including the primary researcher,
the year of publication, and the source of funding.
2. Characteristics of the interventions, including the number
of participants randomised to the treatment and control groups,
the number of total drop-outs per group as well as the number
that dropped out due to adverse effects, the dose of medication
and the period over which it was administered, and the agents
used for treating depression. Details of any psychological therapy
used int he comparator group will be recorded.
3. Characteristics of trial methodology, including the
diagnostic (e.g. DSM-IV-TR) and exclusionary criteria
employed (APA 2000), the screening instrument used (e.g. the
Structured Clinical Interview for DSM-IV) for diagnosis of
depression (Spitzer 1996), the use of a placebo, whether a
minimal severity criterion was employed, the number of centres
involved, and the trial’s rating on the Cochrane Collaboration’s
tool for assessing risk of bias (Higgins 2011).
4. Characteristics of participants, including gender
distribution and mean and range of ages, mean length of time
since diagnosis with depression, whether they have been treated
with medication in the past (treatment naivety), the number of
participants in the sample with depression, and the baseline
severity of depression, as assessed by the trial’s primary outcome
measure or another commonly employed scale.
5. Outcome measures employed, and a summary of
continuous (means and standard deviations) and dichotomous
(frequencies and percentages) data provided. Additional
information will be included, such as whether data reflected the
intent-to-treat with last observation carried forward or
completer/observed cases sample, and the minimal period
required for inclusion of participants in the last observation
carried forward analyses. Other methods of estimating the
outcome for participants who dropped out of the study, such as
the mixed-effects model, will also be recorded.
6. Quality assessment, including the number of randomised
participants who were not included in the analysis (lost to
follow-up), whether blinding occurred for the assessor(s),
patients, or those who administered medication, as well as
whether the allocation of medication was randomised and the
allocation sequence was concealed (the methods used in
implementing these respective bias reduction measures will also
be documented).
The following information will be collated from non-randomised
trials.
1. Description of the studies, including the primary
researcher, the year of publication, and the source of funding.
2. Characteristics of the study, including the number of
participants (per group if groups identified), the number of total
drop-outs per as well as the number that dropped out due to
adverse effects, the dose of medication and the period over which
it was administered, and the agents used for treating depression.
Details of any psychological therapy used in the comparator
group (if any) will be recorded.
3. Characteristics of study methodology, including the
diagnostic (e.g. DSM-IV-TR) and exclusionary criteria
employed (APA 2000), the screening instrument used (e.g. the
Structured Clinical Interview for DSM-IV (SCID)) for diagnosis
of depression (Spitzer 1996), whether a minimal severity
criterion was employed, the number of centres involved.
4. Characteristics of participants, including gender
distribution and mean and range of ages, mean length of time
since diagnosis with depression, whether they have been treated
with medication in the past (treatment naivety), the number of
people in the sample with depression and/or other MH disorders
and the baseline severity of the disorder, as assessed by the study’s
primary outcome measure or another commonly employed scale.
5. Outcome measures employed, and a summary of
continuous (means and standard deviations) and dichotomous
(frequencies and percentages) data provided. Other methods of
estimating the outcome for participants who dropped out of the
study, such as the mixed-effects model, will also be recorded.
6. Quality assessment, including: sample size, clear description
of treatment, representative source of subjects, adequately
selected controls (for case-control studies), use of diagnostic
criteria or inclusion criteria, length of follow-up, loss to follow-
up, whether any form of blinding occurred, outcome measures
described and the use of validated instruments methods used in
implementing these respective bias reduction measures will also
be documented).
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Main planned comparisons
• Antidepressant versus placebo.
• Antidepressant plus one or more additional antidepressants
verus placebo.
• Antidepressant versus psychological therapy.
• Antidepressant plus one or more additional antidepressants
verus psychological therapy.
We will stratify antidepressants in the analyses according to the
categorises as laid out in the Types of interventions section, so
that we do not combine drugs from different classes in analyses.
The group ’Other antidepressants’ will be presented together, but
again only drugs of the same class will be combined to produce a
pooled effect, e.g. duloxetine and venlafaxine.
Assessment of risk of bias in included studies
Assessing quality of non-randomised studies
We are aware of the various limitations of non-randomised stud-
ies. Where the systematic review identifies non-randomised trials,
the quality of the non-randomised selected studies will be assessed
using the guidance from the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). We will consider whether
or not confounding factors (e.g. parity, gravida, planned or un-
planned pregnancy, single mother) were noted or considered and
whether confounding was taken into account by the study design
or analysis. Details of whether or not the baseline characteristics
of the groups being compared was reported will be considered
and a description of how confounding factors were measured, or
fitted as covariates in regression models (e.g. as a continuous, or-
dinal, or grouped categorical variable) will also be provided.The
authors will identify what researchers did to control for selection
bias, including design features of the studies (e.g. matching or
restriction to particular subgroups) and the methods of analysis
(e.g. stratification or regression modelling with propensity scores
or covariates). An additional table will be created listing the pre-
stated confounders as columns, the studies as rows, and indicating
whether each study:
• restricted participant selection so that all groups had the
same value for the confounder (e.g. restricting the study to first
time mothers);
• demonstrated balance between groups for the confounder;
• matched on the confounder; or
• adjusted for the confounder in statistical analyses to
quantify the effect size.
Assessing quality of randomised studies
Risk of bias for all randomised studies will be assessed using the
Cochrane Collaboration’s tool for assessing risk of bias (Higgins
2011). This tool addresses the following domains:
1. selection bias (random sequence generation, allocation
concealment);
2. performance bias (blinding of participants and personnel);
3. detection bias (blinding of outcome assessment);
4. attrition bias (incomplete outcome data);
5. reporting bias (selective outcome reporting);
6. other sources of bias.
Wewill asses sample size, clear description of treatment (e.g. length
of treatment), representative source of subjects, use of diagnostic
criteria or inclusion criteria, outcome measures described and the
use of validated instruments. We will also assess the possibility of
attrition bias due to non-equivalent drop-out rates in the medica-
tion and comparison groups as part of the risk of bias approach.
We will judge each of the six risk of bias domains using the cate-
gories “low risk”, “high risk” or “unclear risk” of bias for all ran-
domised trials, and non-randomised trials for appropriate areas
of assessment of bias (i.e. description of randomisation will not
be applicable for non-randomised trials). All four authors will in-
dependently assess the methodological quality of the trials. Any
disagreements about methodological quality will be resolved by
consultation amongst all authors.
Measures of treatment effect
For continuous variables, we will calculate the mean difference
(MD) or standardised mean difference (SMD) with 95% confi-
dence intervals (CIs). We will combine dichotomous and contin-
uous variables using the standard Cochrane procedure (InOR =
SMD X pi /
√
3) (Higgins 2011).
We will calculate the number needed to treat (NNT) and risk dif-
ference (RD) where appropriate; odds ratio (OR) will be calcu-
lated and converted to an approximate risk ratio (RR) with 95%
CIs for interpretation.
Unit of analysis issues
Studies with multiple treatment groups
In trials comparing the efficacy of multiple medications in treating
depression, wewill split the shared comparison group (e.g. placebo
or psychological therapy) equally between the medication arms as
comparison groups.
Cross-over trials
We will only include cross-over trials in the calculation of the out-
comes of interest when it is: (a) possible to extract medication and
placebo/comparator data from the first treatment period; or (b)
when the inclusion of data from both treatment periods is justi-
fied through a wash-out period of sufficient duration as to min-
imise the risk of carry-over effects. An adequate wash-out period
is defined in accordance with clinical practice as at least two weeks
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for all agents with the exception of fluoxetine, for which a min-
imum wash-out period of four weeks will be required, given the
long plasma half-life of this agent. For trials in which the washout
period is regarded as adequate, data from both periods will only
be included when it is possible to determine the standard error of
the mean difference in response between groups (Elbourne 2002).
The summary statistics required to derive the standard error of in-
terest will be obtained from the trial report, or for trials for which
this information is missing, will be imputed through averaging the
relevant statistic from other included crossover trials with compa-
rable control conditions.
Dealing with missing data
All analyses of dichotomous data will be intention-to-treat. This
will be achieved by including the total number of participants ran-
domised to the different comparison groups as the denominator in
comparisons of treatment response.Wewill only include data from
trials which provide information on the original group size (prior
to drop-outs) in the analyses of treatment response. Preference
will be given to the inclusion of summary statistics for continuous
outcome measures derived from mixed-effects models, followed
by last observation carried forward and observed cases summary
statistics (in that order). This is in line with evidence that mixed-
effects models are more robust to bias than last observation carried
forward analyses (Verbeke 2000).
Assessment of heterogeneity
We will assess heterogeneity of treatment response and symptom
severity visually from the forest plot of relative risk. This will help
determine whether the differences between the results of trials were
greater thanwould be expected by chance alone.Wewill also assess
heterogeneity by means of the chi-squared test of heterogeneity.
If the chi-squared test has a P value of less than 0.10, given the
low power of the chi-square statistic when the number of trials is
small, this will be interpreted as evidence of heterogeneity (Higgins
2011).
In addition, we will use the I2 statistic to determine differences in
effect size across trials that cannot be explained by chance alone
(Higgins 2003). An I2 statistic of greater than 30% and 50%
will arbitrarily be regarded as indicative of moderate and severe
heterogeneity, respectively.
We will assess differences on continuous measures in medication
efficacy between these subgroups by means of Deeks’ stratified test
of heterogeneity (Deeks 2001). This method subtracts the sum of
the chi-square statistics available for each of the subgroups in the
study from the chi-squared statistic available for all the trials, to
provide a measure (Qb) of heterogeneity between groups.
We will determine the differences in treatment response on
the Clinical Global Impression - Improvement scale (CGI-I) by
whether the CIs for the effect sizes of the subgroups overlap. This
method was chosen in preference to the stratified test, due to in-
accuracies in the calculation in Review Manager 2013 of the chi-
squared statistic for dichotomous measures (Higgins 2011).
In recognition of the possibility of differential effects for different
medications, we will stratify all of the outcome comparisons (ex-
cluding subgroup and sensitivity analyses) by the individual an-
tidepressant used.
Assessment of reporting biases
Publication is not necessarily related to study quality and in-
deed publication may imply certain biases (Dickersin 1992; Song
2000). We will detect small-sample effects (including publication
bias) by visual inspection of a funnel plot of treatment response.
However, this method is not robust if there are less than 10 studies
and therefore it will only be carried out in this circumstance (Egger
1997a; Egger 1997b; Egger 2003).
Data synthesis
We will obtain categorical and continuous treatment effects from
a random-effects model (the random-effects model includes both
within-study sampling error and between-studies variation in de-
termining the precision of the confidence interval around the over-
all effect size, whereas the fixed-effect model takes only within-
study variation into account). We will express the outcomes in
terms of an average effect size for each subgroup, as well as by
means of 95% CIs. In trials that incorporate a follow-up phase,
data from the final assessment point will be combined for all out-
come measures. We will stratify comparisons of global treatment
response and reduction of symptom severity on primary and sec-
ondary outcomes by study design (long-term maintenance studies
(>14 weeks) acute treatment interventions).
Subgroup analysis and investigation of heterogeneity
We will undertake subgroup analyses in order to assess the degree
to which clinical and methodological differences between trials
might have systematically influenced differences observed in the
primary treatment outcomes.
We will group the trials according to the following clinical sources
of heterogeneity (number of trials permitting):
1. pregnancy trimester;
2. maternal age;
3. whether or not the sample included patients diagnosed with
other co-morbidities including other mental health issues and
chronic diseases;
4. planned versus unplanned pregnancies.
In addition, the following criteria will be used to assess the extent
of methodological sources of heterogeneity:
1. the involvement of participants from a single centre or
multiple centres. Single-centre trials are more likely to be
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associated with lower sample size but less variability in clinician
ratings;
2. whether or not trials were industry funded. In general,
published trials which are sponsored by pharmaceutical
companies appear more likely to report positive findings than
trials which are not supported by for-profit companies
(Als-Nielsen 2003; Baker 2003);
3. whether or not psychological therapy was implemented
concurrently with pharmacotherapy.
Sensitivity analysis
We will conduct sensitivity analyses to determine the robustness
of our conclusions to methodological assumptions made in con-
ducting the meta-analysis.
1. A sensitivity analysis will be conducted to determine
whether treatment response varies as a function of the use of
treatment response versus non-response as an outcome statistic.
This comparison may be necessary in the light of evidence that
treatment response may result in less consistent outcome
statistics than non-response when the control group event rate is
higher than 50% (Deeks 2002). This sensitivity analysis will
accordingly only be performed if the majority of trials report a
control group event rate higher than 50%.
2. A “worst case/best case” analysis will also be conducted to
determine the influence of the exclusion of participants who
were lost to follow up on the findings of treatment efficacy
(Higgins 2011). In the worst case, all the missing data for the
treatment group will be recorded as non-responders, whereas in
the best case, all missing data in the control group will be treated
as non-responders. Should the conclusions regarding treatment
efficacy not differ between these two comparisons, it can be
assumed that missing data in trial reports do not have a
significant influence on outcome.
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